HC Wainwright Issues Negative Estimate for DNTH Earnings

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Analysts at HC Wainwright cut their Q1 2026 earnings per share estimates for Dianthus Therapeutics in a research note issued on Monday, March 9th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($1.51) per share for the quarter, down from their prior estimate of ($0.92). HC Wainwright has a “Buy” rating and a $130.00 price objective on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q2 2026 earnings at ($1.55) EPS, Q3 2026 earnings at ($1.59) EPS, Q4 2026 earnings at ($1.63) EPS, FY2026 earnings at ($6.21) EPS, FY2027 earnings at ($6.04) EPS, FY2028 earnings at ($6.58) EPS, FY2029 earnings at ($0.58) EPS and FY2030 earnings at $8.98 EPS.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Monday, March 9th. The company reported ($1.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). The firm had revenue of $0.57 million during the quarter, compared to analysts’ expectations of $0.40 million. Dianthus Therapeutics had a negative return on equity of 38.85% and a negative net margin of 7,973.33%.

DNTH has been the subject of several other reports. Oppenheimer boosted their price objective on shares of Dianthus Therapeutics to $145.00 and gave the stock an “outperform” rating in a research note on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, January 21st. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a report on Monday. Stifel Nicolaus set a $120.00 price objective on Dianthus Therapeutics in a research report on Monday. Finally, Raymond James Financial raised Dianthus Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their target price for the stock from $63.00 to $123.00 in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $115.33.

Dianthus Therapeutics Stock Performance

DNTH opened at $80.32 on Thursday. Dianthus Therapeutics has a 1 year low of $13.36 and a 1 year high of $88.02. The firm has a 50 day moving average price of $51.76 and a 200 day moving average price of $42.18. The company has a market cap of $3.57 billion, a PE ratio of -19.59 and a beta of 1.56.

Hedge Funds Weigh In On Dianthus Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Patient Square Capital LP bought a new position in Dianthus Therapeutics during the 3rd quarter valued at $4,919,000. XTX Topco Ltd acquired a new position in Dianthus Therapeutics during the 2nd quarter worth $503,000. Sio Capital Management LLC increased its position in shares of Dianthus Therapeutics by 101.8% in the 2nd quarter. Sio Capital Management LLC now owns 236,070 shares of the company’s stock worth $4,398,000 after purchasing an additional 119,073 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Dianthus Therapeutics by 13.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,642,198 shares of the company’s stock worth $64,620,000 after purchasing an additional 196,117 shares during the last quarter. Finally, Ensign Peak Advisors Inc acquired a new stake in shares of Dianthus Therapeutics in the 2nd quarter valued at about $2,504,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Key Headlines Impacting Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Multiple analyst upgrades/positive notes pushed upside sentiment — Raymond James raised to Strong-Buy, Wedbush and Robert W. Baird published bullish commentary, and Truist raised its price target to $110. Raymond James Upgrade Wedbush Note Baird Note Truist PT Increase
• Neutral Sentiment: Dianthus closed its upsized underwritten offering: 8,470,989 common shares (plus pre-funded warrants), full exercise of the underwriters’ option, at $81.00 for gross proceeds of ~ $719M — strengthens the balance sheet and funds development but increases share count (dilution). Offering Close
• Neutral Sentiment: Prior pricing announcement (pricing of the upsized $625M offering before exercise) set the $81 deal terms and underwriter option that later pushed the deal to $719M; useful for timeline context. Offering Pricing
• Neutral Sentiment: Reported short interest entries show effectively zero reported short volume and a 0.0 days-to-cover figure (data may be placeholder/insignificant) — not a meaningful driver.
• Negative Sentiment: HC Wainwright sharply lowered near‑term and multi‑year EPS forecasts (Q1–Q4 2026 and FY2026–FY2028 trimmed substantially) while keeping a Buy and $130 target — the cuts signal updated modeling for higher costs or slower commercialization timelines and may weigh on near‑term sentiment. HC Wainwright Note (MarketBeat)

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.